IPS Biopharma AG is a privately held, Swiss immuno-oncology focused biotech company developing a potentially first-in-class immunotherapy for solid tumor cancers. The company’s lead drug candidate, IP-001, is designed to initiate a patient-specific, well-tolerated, systemically active immune response against a patient’s individual cancer. IP-001, also known as N-dihydrogalactochitosan, is injected intratumorally after a standard-of-care tumor ablation to initiate the immunotherapy. Unique molecular properties and the novel mechanism of action enables IP-001 to trap and retain tumor-targeting information and promote a robust immune response that attacks both the ablated tumor and distant metastases.

Encouraging early clinical data showed shrinkage of both local tumors and distant metastases after ablation + IP-001 treatment. In some patients, this led to elimination of the cancer with long-lasting response. The company has partnered with the Swiss Group for Clinical Cancer Research (SAKK) for clinical trial development and implementation of its Swiss phase I/II multicenter study that addresses significant clinical unmet need in various indications.

IPS Biopharma AG is an Immunophotonics subsidiary and is supported by the Swiss Foundation for Technological Innovation (STI), be-advanced, the Berne Economic Development Agency (BEDA), is located in the Switzerland Innovation Park and is an active part of the startup community in Switzerland.

Mehr News & Events

Belastungstest für Unterarmschienen

In Zusammenarbeit mit dem Kantonsspital Basel wurde eine Vorrichtung entwickelt mit der statische Belastungstests für 3D gedruckte Unterarmschienen...

Get-together im SIPBB

Am 22. November 2022 fand zum zweiten Mal in diesem Jahr der «get-together Apéro» im SIPBB statt, mit der Intension das interne Networking zwischen...

SSF Netzwerktreffen bei ZESAR.CH in Tavannes

Am 21. November 2022 konnten wir mit einigen Mitgliedern und Freunden der SSF einen spannenden und kurzweiligen Abend bei der Firma ZESAR in Tavann...

This website uses cookies to ensure you get the best experience on our website. By continuing you agree with the our terms of use.